KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash from Operations: 2011-2024

Historic Cash from Operations for Travere Therapeutics (TVTX) over the last 14 years, with Dec 2024 value amounting to -$237.5 million.

  • Travere Therapeutics' Cash from Operations rose 133.68% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.6 million, marking a year-over-year increase of 77.98%. This contributed to the annual value of -$237.5 million for FY2024, which is 27.01% up from last year.
  • According to the latest figures from FY2024, Travere Therapeutics' Cash from Operations is -$237.5 million, which was up 27.01% from -$325.4 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Cash from Operations registered a high of -$42.7 million during FY2020, and its lowest value of -$325.4 million during FY2023.
  • For the 3-year period, Travere Therapeutics' Cash from Operations averaged around -$274.6 million, with its median value being -$260.8 million (2022).
  • As far as peak fluctuations go, Travere Therapeutics' Cash from Operations plummeted by 242.15% in 2022, and later rose by 27.01% in 2024.
  • Yearly analysis of 5 years shows Travere Therapeutics' Cash from Operations stood at -$42.7 million in 2020, then slumped by 78.36% to -$76.2 million in 2021, then slumped by 242.15% to -$260.8 million in 2022, then dropped by 24.73% to -$325.4 million in 2023, then grew by 27.01% to -$237.5 million in 2024.